PI-RADS 4-5分患者靶向穿刺与联合穿刺诊断效能比较
结果显示两种策略检出率无显著差异且一致性高,单独靶向穿刺或可替代联合穿刺。
要点
- PI-RADS 4-5分患者中,单独靶向穿刺与联合穿刺的PCa和csPCa检出率无显著差异。
- 两种策略诊断一致性高(PCa Kappa=0.918,csPCa Kappa=0.958)。
- 单独靶向穿刺术后病理升级率30.5%,联合穿刺为25.9%。
核心结论
- 对PI-RADS 4-5分患者,单独靶向穿刺可获得与靶向联合系统穿刺相近的诊断效果。
研究设计与样本
- 以730例行根治性前列腺切除术患者的术后病理为金标准,比较单独靶向穿刺与联合穿刺的病理升级率。
主要发现
- 两种策略PCa和csPCa检出率差异无统计学意义(P=0.136和P=0.373),一致性Kappa值分别为0.918和0.958(均P<0.001)。
- PI-RADS 4分患者中,单独靶向穿刺与联合穿刺的csPCa检出率分别为59.2%(395/667)和61.5%(410/667),Kappa=0.953(P<0.001)。
- PI-RADS 5分患者中,单独靶向穿刺与联合穿刺的csPCa检出率分别为82.7%(325/393)和83.7%(329/393),Kappa=0.964(P<0.001)。
关键数值与推荐
- 单独靶向穿刺术后病理升级率为30.5%(223/730),其中12.3%(90/730)从病理阴性或ciPCa升级为csPCa。
- 靶向联合系统穿刺术后病理升级率为25.9%(189/730),其中9.9%(72/730)从病理阴性或ciPCa升级为csPCa。
临床怎么用
- 对PI-RADS 4-5分患者,可考虑单独靶向穿刺替代联合穿刺以减少穿刺针数和操作负担。
- 需结合患者个体情况与病理升级风险综合决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the prostate cancer (PCa) detection rates of targeted biopsy (TB) alone versus TB combined with systematic biopsy (SB) in patients with prostate imaging reporting and data systemv2.1 (PI-RADS v2.1) 4-5 lesions on biparametric magnetic resonance imaging. Methods: Clinical data were retrospectively collected from 1 060 patients who underwent combined prostate TB and SB at the First Affiliated Hospital of Nanjing Medical University between March 2018 and December 2023. All patients had pre-biopsy biparametric magnetic resonance imaging with PI-RADS v2.1 category 4 or 5 lesions. A comparative analysis was performed to evaluate the PCa detection rate and clinically significant prostate cancer (csPCa) detection rate between the two biopsy strategies. Using the postoperative pathological findings from 730 patients who underwent radical prostatectomy as the reference standard, a comparison of the pathological upgrading rates between TB alone and the combined biopsy approach was performed. Results: TB alone yielded detection rates of 79.6% (844/1 060) for PCa and 67.9% (720/1 060) for csPCa. The combined biopsy approach yielded detection rates of 82.2% (871/1 060) for PCa and 69.7% (739/1 060) for csPCa. The two strategies demonstrated no significant difference in detection rates of PCa and csPCa (P=0.136 and P=0.373) and showed substantial agreement (Kappa=0.918 for PCa and 0.958 for csPCa, both P<0.001). This diagnostic alignment persisted across subgroups: among patients with PI-RADS category 4 lesions, the csPCa detection rates for TB alone and combined biopsy were 59.2% (395/667) and 61.5% (410/667), respectively, demonstrating high concordance (Kappa=0.953, P<0.001). Among patients with PI-RADS category 5 lesions, the csPCa detection rates for TB alone and combined biopsy were 82.7% (325/393) and 83.7% (329/393), respectively, also demonstrating a high level of agreement (Kappa=0.964, P<0.001). When compared with postoperative pathology, the overall pathological upgrading rates were 30.5% (223/730) for TB alone and 25.9% (189/730) for combined biopsy. The rates of upgrading specifically from biopsy-negative or ciPCa to csPCa were 12.3% (90/730) and 9.9% (72/730), respectively. Conclusion: For patients with PI-RADS 4-5 lesions, TB may serve as a clinically equivalent alternative to combined biopsy, achieving comparable diagnostic efficacy while reducing procedural burden on both patients and healthcare systems. 目的: 评价靶向穿刺和靶向穿刺联合系统穿刺对前列腺影像报告与数据系统(PI-RADS)评分为4~5分患者的前列腺恶性肿瘤检出效能。 方法: 回顾性收集2018年3月至2023年12月在南京医科大学第一附属医院行前列腺靶向穿刺联合系统穿刺的患者1 060例,活检前均行双参数磁共振平扫,PI-RADS评分为4~5分。比较单独靶向穿刺与靶向穿刺联合系统穿刺的前列腺癌(PCa)检出率和临床显著性前列腺癌(csPCa)检出率。以730例行根治性前列腺切除术患者的术后病理结果为金标准,比较单独靶向穿刺与靶向穿刺联合系统穿刺的术后病理升级率。 结果: 单独靶向穿刺的PCa检出率为79.6%(844/1 060),csPCa检出率为67.9%(720/1 060)。靶向穿刺联合系统穿刺的PCa检出率为82.2%(871/1 060),csPCa检出率为69.7%(739/1 060)。单独靶向穿刺与靶向穿刺联合系统穿刺的PCa检出率、csPCa检出率差异均无统计学意义(P值分别为0.136和0.373),PCa、csPCa检出情况均有较好的一致性(Kappa值分别为0.918和0.958,均P<0.001)。按照PI-RADS评分分层分析显示,在PI-RADS评分为4分的患者中,单独靶向穿刺的csPCa检出率为59.2%(395/667),靶向穿刺联合系统穿刺的csPCa检出率为61.5%(410/667),表现出较好的一致性(Kappa=0.953,P<0.001)。在PI-RADS评分为5分的患者中,单独靶向穿刺的csPCa检出率为82.7%(325/393),靶向穿刺联合系统穿刺的csPCa检出率为83.7%(329/393),也具有较好的一致性(Kappa=0.964,P<0.001)。与术后病理结果比较,单独靶向穿刺的术后病理升级率为30.5%(223/730),其中90例(12.3%)患者从单独靶向穿刺病理阴性或临床非显著性前列腺癌(ciPCa)升级为术后病理的csPCa。靶向穿刺联合系统穿刺的术后病理升级率为25.9%(189/730),其中72例(9.9%)患者从靶向穿刺联合系统穿刺病理阴性或ciPCa升级为术后病理的csPCa。 结论: 前列腺PI-RADS评分为4~5分的患者,采用靶向穿刺取代靶向穿刺联合系统穿刺可以获得相近的诊断效果,能够减少患者痛苦,避免医疗资源浪费。.
引用
- Zhang CL, Wang SQ, Shen ZY, et al. [Diagnostic performance analysis of targeted biopsy versus combined targeted and systematic biopsy in patients with PI-RADS 4-5 lesions]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42595553. doi:10.3760/cma.j.cn112152-20250903-00444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。